Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SYDNEY, AUSTRALIA--(Marketwired - Jan 29, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for the...
-
SYDNEY, AUSTRALIA--(Marketwired - Jan 17, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") today announced that the amended CAN-004 protocol was approved by the Belgian...
-
SYDNEY, AUSTRALIA--(Marketwired - Nov 25, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that its recently reported CVac clinical trial...
-
Prima BioMed's CEO to Present at 11th Annual Commercial Translation of Regenerative Medicine Meeting
SYDNEY, AUSTRALIA--(Marketwired - Nov 19, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced that its Chief Executive Officer, Matthew...
-
SYDNEY, AUSTRALIA--(Marketwired - Nov 11, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"), in its most recent quarterly call, provided significant...
-
SYDNEY, AUSTRALIA--(Marketwired - Nov 6, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that it has entered into a...
-
SYDNEY, AUSTRALIA--(Marketwired - Oct 31, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") yesterday released its Appendix 4C - Quarterly Report for...
-
SYDNEY, AUSTRALIA--(Marketwired - Sep 30, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that management will deliver a presentation of...
-
SYDNEY, AUSTRALIA--(Marketwired - Sep 18, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced top-line analysis of the CAN-003 phase 2...
-
SYDNEY, AUSTRALIA--(Marketwired - Sep 11, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") has announced today that Marc Voigt, its Chief Financial...